The recent uptick in M&A on the Indian pharmaceutical market points to tempered valuations and the potential for further consolidation. Scrip spoke to a cross-section of experts including investment bankers on deal street expectations, foreign interest in M&A and whether family-led Indian firms may now be more open to sell-offs.
Two pharma M&A deals on the trot in November have highlighted the softened valuation expectations by sellers on the fragmented Indian market, potentially setting the tone for more consolidation.
On Nov. 3, Torrent Pharmaceuticals Ltd., which is believed to have missed out on a string of prominent acquisitions...